Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions

British Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2008, Pages 529-538

  Muchohi, Simon N ^a   Kokwaro, Gilbert O ^a,b   Ogutu, Bernhards R ^c,d   Edwards, Geoffrey ^e,f   Ward, Steve A ^f   Newton, Charles R J C ^a,g,h  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d U S ARMY   (United States)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Children; Convulsions; Malaria; Midazolam; Pharmacokinetics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; AMODIAQUINE; CHLORAMPHENICOL HEMISUCCINATE; FANSIDAR; FLUMAZENIL; MIDAZOLAM; MIDAZOLAM MALEATE; PENICILLIN G; PHENOBARBITAL; QUININE; THIOPENTAL;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CHILD; CLINICAL ARTICLE; CONVULSION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EPILEPTIC STATE; FEMALE; HUMAN; INFANT; LOADING DRUG DOSE; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADMINISTRATION, BUCCAL; ADOLESCENT; AFRICA; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALARIA, FALCIPARUM; MALE; MIDAZOLAM; PRACTICE GUIDELINES AS TOPIC; SEIZURES; TREATMENT OUTCOME;

EID: 51649114041     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03239.x     Document Type: Article

References (56)

1. Berkley JA, Ross A, Mwangi I, Osier FH, Mohammed M, Shebbe M, Lowe BS, Marsh K, Newton CR. Prognostic indicators of early and late death in children admitted to district hospital in Kenya: cohort study. BMJ 2003 326: 361.
2. Waruiru CM, Newton CR, Forster D, New L, Winstanley P, Mwangi I, Marsh V, Winstanley M, Snow RW, Marsh K. Epileptic seizures and malaria in Kenyan children. Trans R Soc Trop Med Hyg 1996 90: 152 5.
3. van Hensbroek MB, Palmer A, Jaffar S, Schneider G, Kwiatkowski D. Residual neurologic sequelae after childhood cerebral malaria. J Pediatr 1997 131: 125 9.
4. Holding PA, Stevenson J, Peshu N, Marsh K. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999 93: 529 34.
5. Carter JA, Mung'ala-Odera V, Neville BG, Murira G, Mturi N, Musumba C, Newton CR. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatry 2005 76: 476 81.
6. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998 79: 1 53.
7. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998 338: 970 6.
8. Shorvon S. Status epilepticus: Its clinical features and treatment in childhood and adults. Cambridge: Cambridge University Press, 1994.
9. Ogutu BR, Newton CR, Crawley J, Muchohi SN, Otieno GO, Edwards G, Marsh K, Kokwaro GO. Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol 2002 53: 49 57.
10. Crawley J, Waruiru C, Mithwani S, Mwangi I, Watkins W, Ouma D, Winstanley P, Peto T, Marsh K. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 2000 355: 701 6.
11. Norris E, Marzouk O, Nunn A, McIntyre J, Choonara I. Respiratory depression in children receiving diazepam for acute seizures: a prospective study. Dev Med Child Neurol 1999 41: 340 3.
12. Dundee JW, Gamble JA, Assaf RA. Letter: plasma-diazepam levels following intramuscular injection by nurses and doctors. Lancet 1974 2: 1461.
13. Rey E, Delaunay L, Pons G, Murat I, Richard MO, Saint-Maurice C, Olive G. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 1991 41: 355 7.
14. Rainbow J, Browne GJ, Lam LT. Controlling seizures in the prehospital setting: diazepam or midazolam? J Paediatr Child Health 2002 38: 582 6.
15. Vilke GM, Sharieff GQ, Marino A, Gerhart AE, Chan TC. Midazolam for the treatment of out-of-hospital pediatric seizures. Prehosp Emerg Care 2002 6: 215 7.
16. Bell DM, Richards G, Dhillon S, Oxley JR, Cromarty J, Sander JW, Patsalos PN. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res 1991 10: 183 90.
17. Payne K, Mattheyse FJ, Liebenberg D, Dawes T. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989 37: 267 72.
18. Shah I, Deshmukh CT. Intramuscular midazolam vs. intravenous diazepam for acute seizures. Indian J Pediatr 2005 72: 667 70.
19. Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997 13: 92 4.
20. Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics 2008 121: e58 64.
21. Baysun S, Aydin OF, Atmaca E, Gurer YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila) 2005 44: 771 6.
22. Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. Brain Dev 2003 25: 275 8.
23. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999 353: 623 6.
24. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, Martland T, Berry K, Collier J, Smith S, Choonara I. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005 366: 205 10.
25. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992 20: 483 8.
26. Rivera R, Segnini M, Baltodano A, Perez V. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993 21: 991 4.
27. English M, Waruiru C, Amukoye E, Murphy S, Crawley J, Mwangi I, Peshu N, Marsh K. Deep breathing in children with severe malaria: indicator of metabolic acidosis and poor outcome. Am J Trop Med Hyg 1996 55: 521 4.
28. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989 71: 441 59.
29. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 1997 43: 245 52.
30. Park GR, Miller E, Navapurkar V. What changes drug metabolism in critically ill patients? - II Serum inhibits the metabolism of midazolam in human microsomes. Anaesthesia 1996 51: 11 5.
31. Rey E, Treluyer JM, Pons G. Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet 1999 36: 409 24.
32. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Winstanley P, Warn P, Peshu N, Pasvol G, Snow RW. Indicators of life-threatening malaria in African children. N Engl J Med 1995 332: 1399 404.
33. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000 94 (Suppl. 1 S1 90.
34. Winstanley PA, Mberu EK, Watkins WM, Murphy SA, Lowe B, Marsh K. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: unbound quinine concentrations following a simple loading dose regimen. Trans R Soc Trop Med Hyg 1994 88: 577 80.
35. Berkley J, Mwarumba S, Bramham K, Lowe B, Marsh K. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 1999 93: 283 6.
36. Kokwaro GO, Muchohi SN, Ogutu BR, Newton CR. Chloramphenicol pharmacokinetics in African children with severe malaria. J Trop Pediatr 2006 52: 239 43.
37. Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Edwards G, Watkins WM, Kokwaro GO. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol 2003 56: 112 9.
38. Kokwaro GO, Ogutu BR, Muchohi SN, Otieno GO, Newton CR. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol 2003 56: 453 7.
39. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997 15: 357 65.
40. Muchohi SN, Ward SA, Preston L, Newton CR, Edwards G, Kokwaro GO. Determination of midazolam and its major metabolite 1′-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. J Chromatogr B Analyt Technol Biomed Life Sci 2005 821: 1 7.
41. Heinzel G, Woloszczak R, Thomann P. TopFit (Version 2.0): Pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer, Schering AG, 1993.
42. Gibaldi M, Perrier DG. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982.
43. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence, 2nd edn. London: BMJ Books, 2000.
44. Scott RC, Besag FM, Boyd SG, Berry D, Neville BG. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia 1998 39: 290 4.
45. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983 16 (Suppl. 1 43S 49S.
46. Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, Tehiry C, Desplanques L, Mussat P. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994 56: 615 25.
47. Swart EL, de Jongh J, Zuideveld KP, Danhof M, Thijs LG, Strack van Schijndel RJ. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis 2005 45: 360 71.
48. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992 51: 715 28.
49. Swart EL, Zuideveld KP, de Jongh J, Danhof M, Thijs LG, Strack van Schijndel RM. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol 2004 57: 135 45.
50. Hughes J, Gill AM, Mulhearn H, Powell E, Choonara I. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother 1996 30: 27 30.
51. Yakinci C, Mungen B, Sahin S, Karabiber H, Durmaz Y. Midazolam in treatment of various types of seizures in children. Brain Dev 1997 19: 571 2.
52. Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol 2002 17: 106 10.
53. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 1999 66: 454 60.
54. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991 41: 573 8.
55. Dundee JW, Collier PS, Carlisle RJ, Harper KW. Prolonged midazolam elimination half-life. Br J Clin Pharmacol 1986 21: 425 9.
56. Chin RF, Verhulst L, Neville BG, Peters MJ, Scott RC. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry 2004 75: 1584 8.